Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630370 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome
A Phase 2 study, sponsored by Procter and Gamble.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00630370: Clinical Trial Phase 2 study, sponsored by Procter and Gamble.
NCT00630370 is a Phase 2 study that was terminated before completion, run by Procter and Gamble. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00630370, a Phase 2 study, was terminated before completion, sponsored by Procter and Gamble.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
To assess the efficacy of 3 oral dosing regimens of ATI 7505 compared to placebo in patients with PDS by comparing at the end of Day 42 the percentage of patients in each treatment group who have had adequate relief of postprandial distress syndrome symptoms on at least 50% of the treatment days.
Interventions
- DRUG Placebo
- DRUG 20 mg ATI 7505
- DRUG 40 mg ATI 7505
- DRUG 80 mg ATI 7505
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Why NCT00630370 stopped before completion
NCT00630370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00630370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00630370 about?
NCT00630370 is a clinical study titled "A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome". To assess the efficacy of 3 oral dosing regimens of ATI 7505 compared to placebo in patients with PDS by comparing at the end of Day 42 the percentage of patients in each treatment group who have had adequate relief of postprandial distress syndrome symptoms on at least 50% of the treatment days.
What is the current status of trial NCT00630370?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00630370?
The interventions under investigation include: Placebo (DRUG), 20 mg ATI 7505 (DRUG), 40 mg ATI 7505 (DRUG), 80 mg ATI 7505 (DRUG).
Who is sponsoring clinical trial NCT00630370?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00630370's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia